Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death

Forensic Science International

Volumn 234, Issue , 2014, Pages

  Poklis, Justin L ^a   Devers, Kelly G ^b   Arbefeville, Elise F ^b   Pearson, Julia M ^b   Houston, Eric ^c   Poklis, Alphonse ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Hillsborough Co Med Examiner Dept   (United States)

^c Tampa Police Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 IODO 2,5 DIMETHOXYPHENYL) N [(2 METHOXYPHENYL)METHYL]ETHANAMINE; DESIGNER DRUG; PHENETHYLAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOPSY; BEHAVIOR CHANGE; BILE; BLOOD ANALYSIS; BRAIN TISSUE; CASE REPORT; CHEMICAL STRUCTURE; DRUG USE; FORENSIC TOXICOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INTOXICATION; MALE; PRIORITY JOURNAL; STOMACH CONTENT; TANDEM MASS SPECTROMETRY; URINALYSIS; VITREOUS BODY; YOUNG ADULT;

25I-NBOME; BATH SALTS; DESIGNER DRUGS; HPLC/MS/MS;

BENZYLAMINES; BILE; BRAIN CHEMISTRY; CHROMATOGRAPHY, LIQUID; DESIGNER DRUGS; FORENSIC TOXICOLOGY; GASTROINTESTINAL CONTENTS; HUMANS; LIVER; MALE; MOLECULAR STRUCTURE; PAPER; PHENETHYLAMINES; POSTMORTEM CHANGES; TANDEM MASS SPECTROMETRY; VITREOUS BODY; YOUNG ADULT;

EID: 84891322827     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2013.10.015     Document Type: Article

References (42)

1. Kelly J.P. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal. 2011, 3:439-453.
2. Zaitsu K., Katagi M., Tatsuno M., Sato T., Tsuchihashi H., Suzuki K. Recently abused b-keto derivatives of 3,4-methylenedioxyphenylalkylamines: a review of their metabolisms and toxicological analysis. Forensic Toxicol. 2011, 29:73-84.
3. Schifano F., Albanese A., Fergus S., Stair J.L., Deluca P., Corazza O., Davey Z., Corkery J., Siemann H., Scherbaum N., Farre' M., Torrens M., Demetrovics Z., Ghodse A.H., Mephedrone (4-Methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology (Berlin) 2011, 214:593-602.
4. Brandt S.D., Sumnall H.R., Measham F., Cole J. Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test Anal. 2010, 2:377-382.
5. Brandt S.D., Freeman S., Sumnall H.R., Measham F., Cole J. Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones. Drug Test Anal. 2011, 3:569-575.
6. Coppola M., Mondola R. 3,4-Methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol. Lett. 2012, 208:12-15.
7. Gibbons S. 'Legal highs' - novel and emerging psychoactive drugs: a chemical overview for the toxicologist. Clin. Toxicol. (Phila.) 2012, 50:15-24.
8. Spiller H.A., Ryan M.L., Weston R.G., Jansen J. Clinical experience with and analytical confirmation of bath salts and legal highs (synthetic cathinones) in the United States. Clin. Toxicol. (Phila.) 2011, 6:499-505.
9. Murphy C.M., Dulaney A.R., Beuhler M.C., Kacinko S. Bath salts and plant food products: the experience of one regional US poison center. J. Med. Toxicol. 2013, 9:42-48.
10. Lusthof K.J., Oosting R., Maes A., Verschraagen M., Dijkhuizen A., Sprong A.G.A. A case of extreme agitation and death after the use of mephedrone in the Netherlands. Forensic Sci. Int. 2011, 206:e93-e95.
11. Pearson J.M., Hargraves T.L., Hair L.S., Massucci C.J., 3rd Frazee C.C., Garg U., Pietak B.R. Three fatal intoxications due to methylone. J. Anal. Toxicol. 2012, 36:444-451.
12. Cawrse B.M., Levine B., Jufer R.A., Fowler D.R., Vorce S.P., Dickson A.J., Holler J.M. Distribution of methylone in four postmortem cases. J. Anal. Toxicol. 2012, 36:434-439.
13. Cosbey S.H., Peters K.L., Quinn A., Bentley A. Mephedrone (methylmethcathinone) in toxicology casework: a Northern Ireland perspective. J. Anal. Toxicol. 2013, 37:74-82.
14. Murray B.L., Murphy C.M., Beuhler M.C. Death following recreational use of designer drug bath salts containing 3,4-methylenedioxypyrovalerone (MDPV). J. Med. Toxicol. 2012, 8:69-75.
15. Wyman J.F., Lavins E.S., Engelhart D., Armstrong E.J., Snell K.D., Boggs P.D., Taylor S.M., Norris R.N., Miller F.P. Postmortem tissue distribution of MDPV following lethal intoxication by bath salts. J. Anal. Toxicol. 2013, 37:182-185.
16. Namera A., Urabe S., Saito T., Torikoshi-Hatano A., Shiraishi H., Arima Y., Nagao M. A fatal case of 3,4-methylenedioxypyrovalerone poisoning: coexistence of a-pyrrolidinobutiophenone and a-pyrrolidinovalerophenone in blood and/or hair. Forensic Toxicol. 2013, 31:338-343.
17. Saito T., Namera A., Osawa M., Aoki H., Inokuchi S. SPME-GC-MS analysis of α-pyrrolidinovaleorophenone in blood in a fatal poisoning case. Forensic Toxicol. 2013, 31:328-332.
18. Fass J.A., Fass A.D., Garcia A.S. Synthetic cathinones (bath salts): legal status and patterns of abuse. Ann. Pharmacother. 2012, 46:436-441.
19. Zuba D., Sekula K., Buczek A. 25C-NBOMe - new potent hallucinogenic substance identified on the drug market. Forensic Sci. Int. 2013, 227:7-14.
20. Shulgin A.T., Carter M.F. Centrally active phenethylamines. Psychopharmacol. Commun. 1975, 1:93-98.
21. Glennon R.A., Kier L.B., Shulgin A.T. Molecular connectivity analysis of hallucinogenic mescaline analogs. J. Pharm. Sci. 1979, 68:906-907.
22. Shulgin A., Shulgin A. PIHKAL: A Chemical Love Story 1991, Transform Press, Berkeley, CA.
23. Pertz H.H., Heim R., Elz S. N-Benzylated phenylethanamines are highly potent partial agonists at 5-HT2A receptors. Arch. Pharm. Pharm. Med. Chem. 2000, 333:30. (abstract).
24. Heim R., Pertz H.H., Elz S. Partial 5-HT2A-receptor agonists of the phenylethanamine series: effect of a trifluoromethyl substituent. Arch. Pharm. Pharm. Med. Chem. 2000, 333:45. (abstract).
25. Heim R. Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts 2003, Free University of Berlin, Berlin, Germany.
26. Braden M.R., Parrish J.C., Naylor J.C., Nichols D.E. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol. Pharmacol. 2006, 70:1956-1964.
27. Nichols D.E., Frescas S.P., Chemel B.R., Rehder K.S., Zhong D., Lewin A.H. High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand. Bioorg. Med. Chem. 2008, 16:6116-6123.
28. Dean B.V., Stellpflug S.J., Burnett A.M., Engebretsen K.M. 2C or not 2C: phenethylamine designer drug review. J. Med. Toxicol. 2013, 9:172-178.
29. González-Maeso J., Weisstaub N.V., Zhou M., Chan P., Ivic L., Ang R., Lira A., Bradley-Moore M., Ge Y., Zhou Q., Sealfon S.C., Gingrich J.A. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 2007, 53:439-452.
30. Abbas A., Roth B.L. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin. Pharmacother. 2008, 9:3251-3259.
31. Ettrup A., Hansen M., Santini M.A., Paine J., Gillings N., Palner M., Lehel S., Herth M.M., Madsen J., Kristensen J., Begtrup M., Knudsen G.M. Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:681-693.
32. 11C]Cimbi-36. Mol. Imaging Biol. 2013, 15:376-383.
33. Poklis J.L., Charles J., Wolf C., Poklis A. High performance liquid chromatography tandem mass spectrometry method for the determination of 2CC-NBOMe and 25I-NBOMe in human serum. Biomed. Chromatogr. 2013, (Epub ahead of print).
34. Novák J., Janák J. Comments on the standard addition method used in quantitative gas chromatographic analysis. J. Chromatogr. 1967, 28:392-395.
35. US Food and Drug Administration Guidance for Industry: Bioanalytical Method Validation 2001, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD.
36. Kelly A., Eisenga B., Riley B., Judge B. Case series of 25I-NBOMe exposures with laboratory confirmation. Clin. Toxicol. (Phila.) 2012, 50:702. (abstract).
37. Rose S.R., Cumpston K.L., Stromberg P.E., Wills B.K. Severe poisoning following self-reported use of 25-I, a novel substituted amphetamine. Clin. Toxicol. (Phila.) 2012, 50:707-708. (abstract).
38. Rose R.S., Poklis J.L., Poklis A. A case of 25I-NBOMe (25-I) intoxication: a new potent 5HT2a agonist designer drug. Clin. Toxicol. 2013, 51:174-177.
39. Hill S.L., Doris T., Gurung S., Katebe S., Lomas A., Dunn M., Blain P., Thomas S.H. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin. Toxicol. (Phila.) 2013, 51:487-492.
40. Stellpflug S.J., Kealey S.E., Hegarty C.B., Janis G.C. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing. J. Med. Toxicol. 2013, (Epub ahead of print).
41. Baumann M.H., Partilla J.S., Lehner K.R. Psychoactive bath salts: not so soothing. Eur. J. Pharmacol. 2011, 689:1-5.
42. Poklis J.L., Nanco C.R., Troendle M.M., Wolf C.E., Poklis A. Determination of 4-bromo-2, 5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug. Test. Anal. 2013, (Epub ahead of print).